Effects of tamoxifen versus raloxifene on retinal capillary endothelial cell proliferation

Journal of Ocular Pharmacology and Therapeutics

Volumn 27, Issue 3, 2011, Pages 225-233

  Grigsby, Jeffery G ^a,b   Parvathaneni, Kalpana ^a   Almanza, Miguel A ^a   Botello, Angelica M ^a   Mondragon, Albert A ^a   Allen, Donald M ^b   Tsin, Andrew T C ^a  

^a UNIVERSITY OF TEXAS AT SAN ANTONIO   (United States)

^b UNIVERSITY OF TEXAS OF THE PERMIAN BASIN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTRADIOL; PIGMENT EPITHELIUM DERIVED FACTOR; RALOXIFENE; TAMOXIFEN; TRYPAN BLUE; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL CELL; ARTICLE; CELL ASSAY; CELL COUNT; CELL CULTURE; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; CULTURE MEDIUM; DRUG EFFECT; ENDOTHELIUM CELL; NONHUMAN; RETINA CAPILLARY; RETINA DISEASE; RHESUS MONKEY;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS, HORMONAL; CELL LINE; CELL PROLIFERATION; CELL SURVIVAL; ENDOTHELIAL CELLS; ESTRADIOL; ESTRADIOL ANTAGONISTS; ESTROGENS; EYE PROTEINS; MACACA MULATTA; NERVE GROWTH FACTORS; OSMOLAR CONCENTRATION; RALOXIFENE; RETINAL NEOVASCULARIZATION; RETINAL VESSELS; SELECTIVE ESTROGEN RECEPTOR MODULATORS; SERPINS; TAMOXIFEN; UP-REGULATION; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 79958803492     PISSN: 10807683     EISSN: 15577732     Source Type: Journal    
DOI: 10.1089/jop.2010.0171     Document Type: Article

References (44)

1. Love, R.R., and Philips, J. Oophorectomy for breast cancer: history revisited. J. Natl. Cancer Inst. 94:1433-1434, 2002. (Pubitemid 35243741)
2. Beatson, G.T. On the treatment of inoperable cases of carcinoma of the mamma: suggestions for a new method of treatment with illustrative cases. Lancet 2:104-107, 1896.
3. Lacassagne, A. Hormonal pathogenesis of adenocarcinoma of the breast. Am. J. Cancer 27:217-225, 1936.
4. Jensen, E.V. On the mechanism of estrogen action. Perspect. Biol. Med. 6:47-59, 1962.
5. Lerner, L.J., Holthaus, F.J., Jr., and Thompson, C.R. A non-steroidal estrogen antiagonist 1-(p-2-diethylaminoethoxyphenyl)- 1-phenyl-2-p- methoxyphenyl ethanol. Endocrinology 63:295-318, 1958.
6. Cole, M.P., Jones, C.T., and Todd, I.D. A new anti-oestrogenic agent in late breast cancer. An early clinical appraisal of ICI46474. Br. J. Cancer 25:270-275, 1971.
7. Smith, C.L., and OMalley, B.W. Coregulator function: a key to understanding tissue specificity of selective receptor modulators. Endocr. Rev. 25:45-71, 2004. (Pubitemid 38292038)
8. Tamoxifen. Drugs @ FDA: U.S. Food and Drug Administration Web site. Available at www.accessdata.fda.gov/ scripts/cder/drugsatfda/index.cfm? fuseaction = Search.Label- ApprovalHistory#apphist. Accessed 2010.
9. Fisher, B., Costantino, J.P., Wickerham, D.L., et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J. Natl. Cancer Inst. 90:1371-1388, 1998. (Pubitemid 28439961)
10. Evista. Drugs@FDA: U.S. Food and Drug AdministrationWeb site. Available at www.accessdata.fda.gov/scripts/cder/drug satfda/index.cfm?fuseaction = Search.Label-ApprovalHistory #apphist. Accessed 2010.
11. Buzdar, A.U., Marcus, C., Holmes, F., Hug, V., and Hortobagyi, G. Phase II evaluation of Ly156758 in metastatic breast cancer. Oncology 45:344-345, 1988.
12. Vogel, V.G., Costantino, J.P., Wickerham, D.L., et al. Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 trial: preventing breast cancer. Cancer Prev. Res. (Phila Pa) 3:696-706, 2010.
13. Cuzick, J., Forbes, J., Edwards, R., et al. First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial. Lancet 360:817-824, 2002. (Pubitemid 35257944)
14. Vogel, V.G., Costantino, J.P., Wickerham, D.L., et al. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA 295: 2727-2741, 2006.
15. Zhang, J.J., Jacob, T.J., Valverde, M.A., et al. Tamoxifen blocks chloride channels. A possible mechanism for cataract formation. J. Clin. Invest. 94:1690-1697, 1994.
16. Grady, D., Ettinger, B., Moscarelli, E., et al. Safety and adverse effects associated with raloxifene: multiple outcomes of raloxifene evaluation. Obstet. Gynecol. 104:837-844, 2004. (Pubitemid 40458815)
17. Evista. Eli Lilley Web site. Highlights of prescribing information. Web Page. Available at http://pi.lilly.com/us/ evista-pi.pdf. Accessed 2010.
18. Krolewski, A.S., Warram, J.H., Rand, L.I., Christlieb, A.R., Busick, E.J., and Kahn, C.R. Risk of proliferative diabetic retinopathy in juvenile-onset type 1 diabetes: a 40-yr. followup study. Diabetes Care 9:443-452, 1986. (Pubitemid 16008972)
19. Giddabasappa, A., Bauler, M., Yepuru, M., Chaum, E., Dalton, J.T., and Eswaraka, J. 17-beta estradiol protects ARPE-19 cells from oxidative stress through estrogen receptor- beta. Invest. Ophthalmol. Vis. Sci. 51:5278-5287, 2010.
20. Ogueta, S.B., Schwartz, S.D., Yamashita, C.K., and Farber, D.B. Estrogen receptor in the human eye: influence of gender and age on gene expression. Invest. Ophthalmol. Vis. Sci. Aug 40:1906-1911, 1999. (Pubitemid 29365151)
21. Murphy, R.P., Nanda, M., Plotnick, L., Enger, C., Vitale, S., and Patz, A. The relationship of puberty to diabetic retinopathy. Arch. Ophthalmol. 108:215-218, 1990. (Pubitemid 20058152)
22. Olsen, B.S., Sjolie, A.K., Hougaard, P., et al. The significance of the prepubertal diabetes duration for the development of retinopathy and nephropathy in patients with type 1 diabetes. J. Diabetes Complicat. 18:160-164, 2004. (Pubitemid 38622544)
23. Bell, D.S.H. Lack of long-term diabetic complications in spite of poor glycemic control in twins with pure gonadal dysgenesis. Diabetes Care 18:1286-1287, 1995.
24. Moloney, J.B., and Drury, M.I. The effect of pregnancy on the natural course of diabetic retinopathy. Am. J. Ophthalmol. 93:745-756, 1982. (Pubitemid 12120317)
25. Suzuma, I., Mandai, M., Takagi, H., et al. 17 Beta-estradiol increases VEGF receptor-2 and promotes DNA synthesis in retinal microvascular endothelial cells. Invest. Ophthalmol. Vis. Sci. 40:2122-2129, 1999. (Pubitemid 29365178)
26. Aiello, L.P., Avery, R.L., Arrigg, P.G., et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N. Engl. J. Med. 331: 1480-1487, 1994. (Pubitemid 24356306)
27. Folkman, J. Tumor angiogenesis: therapeutic implications. N. Engl. J. Med. 285:1182-1186, 1971.
28. Mueller, M.D., Vigne, J.L., Minchenko, A., Lebovic, D.I., Leitman, D.C., and Taylor, R.N. Regulation of vascular endothelial growth factor (VEGF) gene transcription by estrogen receptors alpha and beta. Proc. Natl. Acad. Sci. U.S.A. 97:10972-10977, 2000.
29. Tombran-Tink, J., Chader, G.G., and Johnson, L.V. PEDF: a pigment epithelium-derived factor with potent neuronal differentiative activity. Exp. Eye Res. 53:411-414, 1991.
30. Tombran-Tink, J., and Johnson, L.V. Neuronal differentiation of retinoblastoma cells induced by medium conditioned by human RPE cells. Invest. Ophthalmol. Vis. Sci. 30:1700-1707, 1989. (Pubitemid 19214990)
31. Takenaka, K., Yamagishi, S., Jinnouchi, Y., Nakamura, K., Matsui, T., and Imaizumi, T. Pigment epithelium-derived factor (PEDF)-induced apoptosis and inhibition of vascular endothelial growth factor (VEGF) expression in MG63 human osteosarcoma cells. Life Sci. 77:3231-3241, 2005. (Pubitemid 41433323)
32. Dawson, D.W., Volpert, O.V., Gillis, P., et al. Pigment epithelium- derived factor: a potent inhibitor of angiogenesis. Science 285:245-248, 1999. (Pubitemid 29329995)
33. Gao, G., Li, Y., Zhang, D., Gee, S., Crosson, C., and Ma, J. Unbalanced expression of VEGF and PEDF in ischemiainduced retinal neovascularization. FEBS Lett. 489:270-276, 2001. (Pubitemid 32126422)
34. Cheung, L.W., Au, S.C., Cheung, A.N., et al. Pigment epithelium-derived factor is estrogen sensitive and inhibits the growth of human ovarian cancer and ovarian surface epithelial cells. Endocrinology 147:4179-4191, 2006. (Pubitemid 44268369)
35. Brar, V.S., Sharma, R.K., Murthy, R.K., and Chalam, K.V. Evaluation of differential toxicity of varying doses of bevacizumab on retinal ganglion cells, retinal pigment epithelial cells, and vascular endothelial growth factor-enriched choroidal endothelial cells. J. Ocul. Pharmacol. Ther. 25:507-511, 2009.
36. Amrite, A.C., Ayalasomayajula, S.P., Cheruvu, N.P., and Kompella, U.B. Single periocular injection of celecoxib- PLGA microparticles inhibits diabetes-induced elevations in retinal PGE2, VEGF, and vascular leakage. Invest. Ophthalmol. Vis. Sci. 47:1149-1160, 2006. (Pubitemid 46768351)
37. NCBI. Entrez, The Life Sciences Search Engine. Web Page. Available at www.ncbi.nlm.nih.gov/sites/gquery. Accessed 2011.
38. Katzung, B.G., ed. Lange Basic and Clinical Pharmacology, 10th edition. San Francisco, CA: McGraw Hill Medical; 2007.
39. Wilson, J.D., Foster, D.W., Kronenberg, H.M., and Larsen, P.R., eds. Williams Textbook of Endocrinology, 9th edition. Toronto, Ontario, Canada: W.B. Saunders; 1998.
40. Osborne, C.K., Zhao, H., and Fuqua, S.A. Selective estrogen receptor modulators: structure, function, and clinical use. J. Clin. Oncol. 18:3172-3186, 2000.
41. Manni, A., and Verderame, M., eds. Selective Estrogen Receptor Modulators: Research and Clinical Applications, 1st edition. Totowa, NJ: Humana Press; 2002.
42. Rudnicka, A.R., and Birch, J. Diabetic Eye Disease, 1st edition. Oxford, England: Butterworth/Heinemann; 2000.
43. Harmey, J., ed. VEGF and Cancer. Georgetown, TX: Landes Bioscience; 2004.
44. Garner, A. Histopathology of diabetic retinopathy in man. Eye 7 (Pt 2):250-253, 1993. (Pubitemid 23153118)